David Salant is a Nephrology physician affiliated with Boston University. OpenAlex indexes 244 publications with 16,248 citations (h-index 62). By OpenAlex citation count, this profile ranks in the top 10% of Nephrology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
725 Albany Street
Shapiro 7, Suite A
Boston, MA 021182526
Telephone
617-414-8601Provider last certified this registry record 3 Feb 2021.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20231 payment
- PFIZER INC.Program year20222 payments
- Otsuka Pharmaceutical Co., Ltd.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
62.6%Loop diuretic19.8%Torsemide54%Furosemide46%Part D<11 patientsACE inhibitor16.6%Lisinopril100%Part D≥12 patients+ 3 more classes in this area
Metabolism & gastrointestinal
37.4%Vitamin D3 Analog30.5%Calcitriol100%Part D≥14 patientsCorticosteroid7%Prednisone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
8 NIH research awards on record, funded 1986–2016 per NIH RePORTER. The latest:
- Role of PLA2R and anti-PLA2R in idiopathic membranous nephropathy
Boston Medical Center
FY2015$367,575R01DK090029
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1–associated membranous nephropathy
Journal of Clinical Investigation
2020 - Association of Pathological Fibrosis With Renal Survival Using Deep Neural Networks
Kidney International Reports
2018 - LDL Receptor-Related Protein 2 (Megalin) as a Target Antigen in Human Kidney Anti-Brush Border Antibody Disease
Journal of the American Society of Nephrology
2017
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Holick, MD
Boston University
Gene Kwan, MD
Boston University
Joseph Antin, MD
Boston University
George O'Connor, MD
Boston University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”